Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06708455 · ClinicalTrials.gov registry record · Phase 2
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
A Phase 2 study, sponsored by Rapa Therapeutics.
- Not yet
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT06708455 is a Phase 2 study that has not yet begun recruiting, run by Rapa Therapeutics. The registered enrollment target is 65 participants.
The verdict
NCT06708455, a Phase 2 study, has not yet begun recruiting, sponsored by Rapa Therapeutics.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
The protocol is a Simon's 2-stage, non-randomized, open label, multi-site, phase 2 trial for patients with advanced metastatic, recurrent and unresectable malignant melanoma that has recurred or relapsed after prior anti-PD-(L)1 therapy.
Interventions
- BIOLOGICAL RAPA-201 Rapamycin Resistant T Cells
- DRUG Chemotherapy Prior to RAPA-201 Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2027-03-01 |
| Est. Completion | 2029-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06708455
The ClinicalTrials.gov registry entry for NCT06708455 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rapa Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RAPA-201 Rapamycin Resistant T Cells is the first listed.
NCT06708455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06708455 about?
NCT06708455 is a clinical study titled "Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma". The protocol is a Simon's 2-stage, non-randomized, open label, multi-site, phase 2 trial for patients with advanced metastatic, recurrent and unresectable malignant melanoma that has recurred or relapsed after prior anti-PD-(L)1 therapy.
What is the current status of trial NCT06708455?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2027-03-01. Estimated completion is 2029-09-30.
What interventions are being tested in trial NCT06708455?
The interventions under investigation include: RAPA-201 Rapamycin Resistant T Cells (BIOLOGICAL), Chemotherapy Prior to RAPA-201 Therapy (DRUG).
Who is sponsoring clinical trial NCT06708455?
This trial is sponsored by Rapa Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.